STOCK TITAN

Atossa Therapeutics (ATOS) Financials

ATOS NASDAQ
Trailing 12 months to September 30, 2026
Net Income -$34.7M n/m YoY
EPS (Diluted) -$4.04 FY2025 annual
Free Cash Flow -$35.3M n/m YoY
Operating Cash Flow -$35.3M n/m YoY
Market Cap $15.9M as of Nov 20, 2026
Price / Sales n/m no full year of revenue reported yet
Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to September 30, 2026
Price / Book 0.7x on $21.7M equity, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 20, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2026, filed Nov 10, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ATOS SEC filings page.

This page shows Atossa Therapeutics, Inc. (ATOS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI ATOS FY2025

Atossa remains a development-stage business: research spending is rising while shrinking assets and worsening returns show continued capital consumption.

In FY2025, R&D spending rose 50.1% while assets fell 37.7%, showing intensified development work alongside a contracting financial base. Operating cash flow of -$29.8M was close to the net loss of $34.8M, so reported losses are translating largely into cash consumption rather than being mainly non-cash accounting charges.

Liabilities reached 17.3% of assets in FY2025 versus 6.5% in FY2024, indicating that obligations are occupying a larger share of a shrinking balance sheet. The current ratio remained 5.5x, but that short-term cushion is materially thinner than earlier in the period.

The spending mix is becoming more development-heavy: R&D increased 50.1% while selling, general and administrative costs rose 18.2%. That investment has not yet produced operating improvement, with the operating loss widening from $27.6M to $37.1M between FY2024 and FY2025.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Financial health score not available

We do not publish a peer-relative financial health score for Atossa Therapeutics, Inc., because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.

Piotroski F-Score Partial
1/6

Atossa Therapeutics, Inc. passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality No Cash Backing
N/A

Atossa Therapeutics, Inc. reported a net loss of $34.8M while operations used $29.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA
-$5.9M
YoYn/m
QoQn/m
5Y CAGRn/m

Atossa Therapeutics, Inc.'s EBITDA was -$5.9M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Net Income
-$5.6M
YoYn/m
QoQn/m
5Y CAGRn/m

Atossa Therapeutics, Inc. reported a net loss of $5.6M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)
-$0.56
YoYn/m
QoQn/m

Atossa Therapeutics, Inc. earned -$0.56 per diluted share (EPS) in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Revenue

Not reported for Q3 2026.

Cash & Balance Sheet

Free Cash Flow
-$5.5M
YoYn/m
QoQn/m
5Y CAGRn/m

Atossa Therapeutics, Inc. recorded an outflow of $5.5M in free cash flow in Q3 2026, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Debt
$20.6M
YoY-60.3%
QoQ-21.2%
5Y CAGR-31.9%
10Y CAGR+16.7%

Atossa Therapeutics, Inc. held $20.6M in cash as of Q3 2026; no long-term debt figure is on record for that period.

Shares Outstanding
10M
YoY+15.9%
QoQ0.0%
5Y CAGR+3.4%

Atossa Therapeutics, Inc. had 10M shares outstanding in Q3 2026. This represents an increase of 15.9% from the same quarter a year earlier. It is unchanged from the prior quarter.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Return on Equity
-25.9%
YoY-8.5pp
QoQ+5.7pp
5Y change-22.2pp

Atossa Therapeutics, Inc.'s quarterly ROE was -25.9% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is down 8.5 percentage points from the same quarter a year earlier. Against the prior quarter it is up 5.7 percentage points.

Gross Margin

Not reported for Q3 2026.

Operating Margin

Not reported for Q3 2026.

Net Margin

Not reported for Q3 2026.

Capital Allocation

R&D Spending
$3.4M
YoY-37.1%
QoQ-31.0%
5Y CAGR+8.9%

Atossa Therapeutics, Inc. invested $3.4M in research and development in Q3 2026. This represents a decrease of 37.1% from the same quarter a year earlier. Against the prior quarter it is down 31.0%.

Capital Expenditures
$0
YoY-100.0%
QoQn/m

Atossa Therapeutics, Inc. reported no capital expenditure in Q3 2026. This represents a decrease of 100.0% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Share Buybacks

Not reported for Q3 2026.

ATOS Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ATOS quarterly income statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
R&D Expenses$3.4M-37.1%$4.9M-11.0%$4.8M+15.0%$6.2M+80.8%$5.4M+57.4%$5.5M+54.9%$4.2M+10.9%$3.4M-39.8%
SG&A Expenses$2.5M-35.0%$3.8M+7.3%$5.1M+56.3%$5.3M+40.9%$3.9M+30.5%$3.5M-0.4%$3.3M+0.8%$3.7M+11.4%
Operating Income-$5.9Mn/m-$8.7Mn/m-$9.9Mn/m-$11.4Mn/m-$9.3Mn/m-$9.0Mn/m-$7.4Mn/m-$7.2Mn/m
EBITDA-$5.9Mn/m-$8.7Mn/m-$9.9Mn/m-$11.4Mn/m-$9.2Mn/m-$9.0Mn/m-$7.4Mn/m-$7.1Mn/m
Income Tax$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Net Income-$5.6Mn/m-$8.5Mn/m-$9.6Mn/m-$10.9Mn/m-$8.7Mn/m-$8.4Mn/m-$6.7Mn/m-$6.3Mn/m
EPS (Basic)-$0.56n/m-$0.95n/m-$1.11n/mN/A-$1.01n/m-$0.98n/m-$0.78n/m-$0.75n/m
EPS (Diluted)-$0.56n/m-$0.95n/m-$1.11n/mN/A-$1.01n/m-$0.98n/m-$0.78n/m-$0.75n/m
Diluted Shares (Avg)10M+15.9%9M+3.3%9M0.0%N/A9M+2.8%9M+2.9%9M+3.2%N/A

Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense.

ATOS Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ATOS quarterly balance sheet
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'25FilingQ4'2410-K
Total Assets$26.4M-54.4%$32.3M-50.0%$37.9M-46.4%$47.6M-37.7%$58.0M-27.0%$64.5M-24.9%$70.7M-22.3%$76.4M-20.6%
Current Assets$25.2M-54.8%$31.0M-50.4%$36.7M-46.7%$45.6M-38.7%$55.7M-27.8%$62.5M-23.5%$68.7M-21.0%$74.5M-19.3%
Cash & Equivalents$20.6M-60.3%$26.1M-54.9%$31.7M-51.3%$41.3M-41.9%$51.8M-30.7%$57.9M-27.2%$65.1M-22.4%$71.1M-19.6%
Short-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Long-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Total Liabilities$4.7M-42.7%$5.5M-20.1%$7.5M+37.5%$8.3M+66.2%$8.2M+41.9%$6.8M+19.7%$5.4M+1.8%$5.0M-5.1%
Current Liabilities$4.7M-42.7%$5.5M-20.1%$7.5M+37.5%$8.3M+66.2%$8.2M+41.9%$6.8M+19.7%$5.4M+1.8%$5.0M-5.1%
Non-Current Liabilities$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Total Equity$21.7M-56.3%$26.8M-53.5%$30.5M-53.3%$39.4M-44.9%$49.8M-32.4%$57.7M-28.0%$65.3M-23.8%$71.5M-21.5%
Retained Earnings-$270.3Mn/m-$264.6Mn/m-$256.2Mn/m-$246.6Mn/m-$235.6Mn/m-$226.9Mn/m-$218.5Mn/m-$211.8Mn/m

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

ATOS Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ATOS quarterly cash flow statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Cash Flow-$5.5Mn/m-$9.6Mn/m-$9.6Mn/m-$10.5Mn/m-$6.0Mn/m-$7.3Mn/m-$6.0Mn/m-$7.1Mn/m
Depreciation & Amortization$4K0.0%$4K0.0%$4K0.0%$4K0.0%$4K0.0%$4K0.0%$4K-20.0%$4K-71.4%
Stock-Based Compensation$547K-30.2%$815K+2.4%$722K+28.2%N/A$784K+4.7%$796K+126.1%$563K+35.0%N/A
Capital Expenditures$0-100.0%$0n/m$0-100.0%$7Kn/m$7K-30.0%$0-100.0%$9K+50.0%$0n/m
Free Cash Flow-$5.5Mn/m-$9.6Mn/m-$9.6Mn/m-$10.5Mn/m-$6.0Mn/m-$7.3Mn/m-$6.0Mn/m-$7.1Mn/m
Investing Cash Flow$0n/m$0n/m$0n/m-$7Kn/m-$7Kn/m$0n/m-$9Kn/m$0n/m
Financing Cash Flow$0n/m$4.0Mn/m$0n/m$0-100.0%$0n/m$0-100.0%$0-100.0%$3.4Mn/m

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

ATOS Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

ATOS quarterly financial ratios
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Return on Equity-25.9%-8.5pp-31.6%-17.1pp-31.4%-21.2pp-27.8%-18.9pp-17.5%-7.6pp-14.6%-7.0pp-10.3%-3.4pp-8.9%-0.4pp
Return on Assets-21.3%-6.3pp-26.3%-13.2pp-25.3%-15.8pp-23.0%-14.7pp-15.0%-5.9pp-13.1%-6.0pp-9.5%-3.0pp-8.3%-0.2pp
Current Ratio5.35-1.4x5.69-3.5x4.92-7.8x5.53-9.5x6.77-6.5x9.17-5.2x12.67-3.7x14.99-2.6x
Liabilities-to-Equity0.22+0.1x0.20+0.1x0.24+0.2x0.21+0.1x0.17+0.1x0.120.0x0.080.0x0.070.0x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Debt-to-Equity, Asset Turnover, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Atossa Therapeutics, Inc. ATOS FY2025 N/A -$34.8M N/A $15.9M —
Lipocine Inc. LPCN FY2025 $2.0M -$9.6M N/A $16.4M 55/100
Cocrystal Pharma, Inc. COCP FY2025 N/A -$8.8M N/A $18.3M —
IGC Pharma, Inc. IGC FY2025 $1.3M -$7.1M N/A $19.6M 44/100
Estrella Immunopharma, Inc. ESLA FY2025 N/A -$13.1M N/A $14.1M —
Cel-Sci Corporation CVM FY2025 N/A -$25.4M N/A $21.3M —

Frequently Asked Questions

No, Atossa Therapeutics, Inc. (ATOS) reported a net loss of $34.7M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net loss of $34.8M.

Atossa Therapeutics, Inc. (ATOS) reported diluted earnings per share of -$4.04 for fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Atossa Therapeutics, Inc. (ATOS) had EBITDA of -$37.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

Atossa Therapeutics, Inc. (ATOS) has a return on equity of -88.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Atossa Therapeutics, Inc. (ATOS) recorded an outflow of $29.8M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Atossa Therapeutics, Inc. (ATOS) recorded an outflow of $29.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

Atossa Therapeutics, Inc. (ATOS) had $47.6M in total assets as of fiscal year 2025, including both current and long-term assets.

Atossa Therapeutics, Inc. (ATOS) invested $23K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Atossa Therapeutics, Inc. (ATOS) invested $21.2M in research and development during fiscal year 2025.

Atossa Therapeutics, Inc. (ATOS) had 9M shares outstanding as of fiscal year 2025.

Atossa Therapeutics, Inc. (ATOS) had a current ratio of 5.53 as of fiscal year 2025, which is generally considered healthy.

Atossa Therapeutics, Inc. (ATOS) had a liabilities-to-equity ratio of 0.21 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.

Atossa Therapeutics, Inc. (ATOS) had a return on assets of -73.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Atossa Therapeutics, Inc. (ATOS) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $15.9M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Atossa Therapeutics, Inc. (ATOS) has no price-to-sales ratio at the moment: no full year of revenue reported yet. The market capitalization is $15.9M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2025, Atossa Therapeutics, Inc. (ATOS) held $41.3M in cash, cash equivalents and investments, and reported an operating cash outflow of $29.8M over that year. Dividing the one by the other, the reported balance equals about 17 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Atossa Therapeutics, Inc. (ATOS) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Atossa Therapeutics, Inc. (ATOS) reported a net loss of $34.8M while operations used $29.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Back to top